[go: up one dir, main page]

HUP0003836A2 - Lazofoxifent tartalmazó gyógyszerkészítmények - Google Patents

Lazofoxifent tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0003836A2
HUP0003836A2 HU0003836A HUP0003836A HUP0003836A2 HU P0003836 A2 HUP0003836 A2 HU P0003836A2 HU 0003836 A HU0003836 A HU 0003836A HU P0003836 A HUP0003836 A HU P0003836A HU P0003836 A2 HUP0003836 A2 HU P0003836A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
lasofoxifene
containing lasofoxifene
safe
Prior art date
Application number
HU0003836A
Other languages
English (en)
Inventor
David Duane Thomson
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0003836D0 publication Critical patent/HU0003836D0/hu
Publication of HUP0003836A2 publication Critical patent/HUP0003836A2/hu
Publication of HUP0003836A3 publication Critical patent/HUP0003836A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya gyógyszerkészítmény, amely alkalmas egy ösztrogénagonista/antagonista hatóanyag biztonságos, hatékony vérszintjénekfenntartására egy hosszabb periódusban. Ó
HU0003836A 1999-09-29 2000-09-28 Pharmaceutical compositions containing lasofoxifene HUP0003836A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15665299P 1999-09-29 1999-09-29

Publications (3)

Publication Number Publication Date
HU0003836D0 HU0003836D0 (en) 2000-12-28
HUP0003836A2 true HUP0003836A2 (hu) 2001-10-28
HUP0003836A3 HUP0003836A3 (en) 2002-09-30

Family

ID=22560457

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003836A HUP0003836A3 (en) 1999-09-29 2000-09-28 Pharmaceutical compositions containing lasofoxifene

Country Status (20)

Country Link
US (1) US6436977B1 (hu)
EP (1) EP1092431B1 (hu)
JP (1) JP2001097862A (hu)
KR (1) KR100468246B1 (hu)
AT (1) ATE339201T1 (hu)
AU (1) AU781828B2 (hu)
CA (1) CA2321369C (hu)
CO (1) CO5200833A1 (hu)
CY (1) CY1105235T1 (hu)
DE (1) DE60030654T2 (hu)
DK (1) DK1092431T3 (hu)
ES (1) ES2269071T3 (hu)
HU (1) HUP0003836A3 (hu)
IL (1) IL138634A (hu)
MY (1) MY121519A (hu)
NZ (2) NZ507200A (hu)
PE (1) PE20010680A1 (hu)
PT (1) PT1092431E (hu)
TW (1) TWI224001B (hu)
ZA (1) ZA200005141B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
CA2452874A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
JP2010509370A (ja) * 2006-11-10 2010-03-25 シンダックス ファーマシューティカルズ，インク． 癌の治療用のＥＲα＋リガンドとヒストンデアセチラーゼ阻害剤との組み合わせ
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
US20090131367A1 (en) * 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
EP1004306A3 (en) 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications

Also Published As

Publication number Publication date
IL138634A0 (en) 2001-10-31
JP2001097862A (ja) 2001-04-10
ATE339201T1 (de) 2006-10-15
US6436977B1 (en) 2002-08-20
AU781828B2 (en) 2005-06-16
AU5661800A (en) 2001-04-05
NZ516413A (en) 2004-12-24
CO5200833A1 (es) 2002-09-27
DK1092431T3 (da) 2006-12-18
KR100468246B1 (ko) 2005-01-27
DE60030654T2 (de) 2007-04-05
EP1092431B1 (en) 2006-09-13
EP1092431A2 (en) 2001-04-18
CY1105235T1 (el) 2010-03-03
KR20010061927A (ko) 2001-07-07
NZ507200A (en) 2004-12-24
DE60030654D1 (de) 2006-10-26
HUP0003836A3 (en) 2002-09-30
PT1092431E (pt) 2006-12-29
ES2269071T3 (es) 2007-04-01
EP1092431A3 (en) 2002-02-13
IL138634A (en) 2006-08-01
MY121519A (en) 2006-01-28
CA2321369A1 (en) 2001-03-29
TWI224001B (en) 2004-11-21
PE20010680A1 (es) 2001-06-29
ZA200005141B (en) 2002-03-26
CA2321369C (en) 2007-07-17
HU0003836D0 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
AP1697A (en) Azabicycloalkanes as CCR5 modulators.
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE05034B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende valmistamise meetodid
HUP0000979A1 (hu) FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
EE05400B1 (et) Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
TR200100241T2 (tr) Nosiseptin reseptörü ORL-1 için yüksek çekim gücü olan ligandlar
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
EE200100695A (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
PT1412384E (pt) Formulação estável de glp-1 modificado
EA199900373A2 (ru) Фармацевтические композиции
NO20020208D0 (no) Flytende sammensetninger for oral administrasjon
HK1034183A1 (en) Galenic formulations of meloxicam for oral administration.
HUP0003836A2 (hu) Lazofoxifent tartalmazó gyógyszerkészítmények
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ATE282415T1 (de) Wirkstoffkombinationen enthaltend (e)-7-(4-(4- fluorophenyl)-6-isopropyl-2-
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
HUP0202253A2 (hu) Szelektív iGluR5-receptorantagonisták a migrén kezelésére
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees